Proteomic analysis reveals a proteolytic feedback loop in murine seminal fluid

Prostate

Volumn 73, Issue 13, 2013, Pages 1427-1440

  McKee, Chad M ^a   Xu, Danmei ^a,b   Kessler, Benedikt M ^c,d   Muschel, Ruth J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

metalloproteinase 9; protease nexin 1; seminal fluid proteomics

Indexed keywords

GELATINASE B; PROTEASE NEXIN I; RENIN; SERINE PROTEINASE INHIBITOR; UROKINASE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEOMICS; SEMINAL PLASMA; SEMINAL VESICLE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

METALLOPROTEINASE 9; PROTEASE NEXIN 1; SEMINAL FLUID, PROTEOMICS;

ANIMALS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; PROTEOLYSIS; PROTEOMICS; SEMEN; SEMINAL VESICLES; SERPIN E2;

EID: 84882271026     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22690     Document Type: Article

References (50)

1. Kessenbrock K, Plaks V, Werb Z,. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141 (1): 52-67.
2. Overall CM, Dean RA, Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 2006; 25 (1): 69-75.
3. Duffy MJ, McGowan PM, Gallagher WM,. Cancer invasion and metastasis: Changing views. J Pathol 2008; 214 (3): 283-293.
4. Gialeli C, Theocharis AD, Karamanos NK,. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278 (1): 16-27.
5. Bjorklund M, Koivunen E,. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755 (1): 37-69.
6. Liotta LA, Lee CW, Morakis DJ,. New method for preparing large surfaces of intact human basement membrane for tumor invasion studies. Cancer Lett 1980; 11 (2): 141-152.
7. Psaila B, Lyden D,. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 2009; 9 (4): 285-293.
8. Ries C, Loher F, Zang C, Ismair MG, Petrides PE,. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999; 5 (5): 1115-1124.
9. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z,. MMP-9/gelatinase B is a key regulator of growild typeh plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93 (3): 411-422.
10. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D,. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438 (7069): 820-827.
11. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR,. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003; 10 (11): 823-832.
12. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC,. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2 MMP-9) markers of prostate cancer. Urol Res 2005; 33 (1): 44-50.
13. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME,. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15 (3): 246-258.
14. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002; 295 (5564): 2387-2392.
15. Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, Kessler BM,. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 2008; 7 (11): 2215-2228.
16. Xu D, McKee CM, Cao Y, Ding Y, Kessler BM, Muschel RJ,. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res 2010; 70 (17): 6988-6998.
17. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K,. Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209 (2): 213-218.
18. Stone SR, Nick H, Hofsteenge J, Monard D,. Glial-derived neurite-promoting factor is a slow-binding inhibitor of trypsin, thrombin, and urokinase. Arch Biochem Biophys 1987; 252 (1): 237-244.
19. Baker JB, Low DA, Simmer RL, Cunningham DD,. Protease-nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21 (1): 37-45.
20. Mansilla S, Boulaftali Y, Venisse L, Arocas V, Meilhac O, Michel JB, Jandrot-Perrus M, Bouton MC,. Macrophages and platelets are the major source of protease nexin-1 in human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2008; 28 (10): 1844-1850.
21. Fayard B, Bianchi F, Dey J, Moreno E, Djaffer S, Hynes NE, Monard D,. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res 2009; 69 (14): 5690-5698.
22. Rosenblatt DE, Cotman CW, Nieto-Sampedro M, Rowe JW, Knauer DJ,. Identification of a protease inhibitor produced by astrocytes that is structurally and functionally homologous to human protease nexin-I. Brain Res 1987; 415 (1): 40-48.
23. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB,. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci USA 1986; 83 (4): 996-1000.
24. Boulaftali Y, Ho-Tin-Noe B, Pena A, Loyau S, Venisse L, Francois D, Richard B, Arocas V, Collet JP, Jandrot-Perrus M, Bouton MC,. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 2011; 123 (12): 1326-1334.
25. Eaton DL, Scott RW, Baker JB,. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259 (10): 6241-6247.
26. Thompson M, Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD, Pollack JR,. Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate 2008; 68 (11): 1248-1256.
27. Daimon E, Wada Y,. Role of neutrophils in matrix metalloproteinase activity in the preimplantation mouse uterus. Biol Reprod 2005; 73 (1): 163-171.
28. Morrison CJ, Butler GS, Rodriguez D, Overall CM,. Matrix metalloproteinase proteomics: Substrates, targets, and therapy. Curr Opin Cell Biol 2009; 21 (5): 645-653.
29. Batycka M, Inglis NF, Cook K, Adam A, Fraser-Pitt D, Smith DG, Main L, Lubben A, Kessler BM,. Ultra-fast tandem mass spectrometry scanning combined with monolithic column liquid chromatography increases throughput in proteomic analysis. Rapid Commun Mass Spectrom 2006; 20 (14): 2074-2080.
30. Wright CA, Howles S, Trudgian DC, Kessler BM, Reynard JM, Noble JG, Hamdy FC, Turney BW,. Label-free quantitative proteomics reveals differentially regulated proteins influencing urolithiasis. Mol Cell Proteomics 2011; 10 (8): 74-86.
31. Vassalli JD, Huarte J, Bosco D, Sappino AP, Sappino N, Velardi A, Wohlwend A, Erno H, Monard D, Belin D,. Protease-nexin I as an androgen-dependent secretory product of the murine seminal vesicle. EMBO J 1993; 12 (5): 1871-1878.
32. Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L,. PC cell-derived growild typeh factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res 2004; 10 (4): 1333-1337.
33. Lin MH, Lee RK, Hwu YM, Lu CH, Chu SL, Chen YJ, Chang WC, Li SH,. SPINKL, a Kazal-type serine protease inhibitor-like protein purified from mouse seminal vesicle fluid, is able to inhibit sperm capacitation. Reproduction. 2008; 136 (5): 559-571.
34. Ou CM, Tang JB, Huang MS, Sudhakar Gandhi PS, Geetha S, Li SH, Chen YH,. The mode of reproductive-derived Spink (serine protease inhibitor Kazal-type) action in the modulation of mammalian sperm activity. Int J Androl 2012; 35 (1): 52-62.
35. Lu CH, Lee RK, Hwu YM, Chu SL, Chen YJ, Chang WC, Lin SP, Li SH,. SERPINE2, a serine protease inhibitor extensively expressed in adult male mouse reproductive tissues, may serve as a murine sperm decapacitation factor. Biol Reprod 2011; 84 (3): 514-525.
36. Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, Barreda C, Watts S, Baker JB,. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985; 260 (11): 7029-7034.
37. Knauer MF, Hawley SB, Knauer DJ,. Identification of a binding site in protease nexin I (PN1) required for the receptor mediated internalization of PN1-thrombin complexes. J Biol Chem 1997; 272 (19): 12261-12264.
38. Crisp RJ, Knauer DJ, Knauer MF,. Roles of the heparin and low density lipid receptor-related protein-binding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism. The PN1 heparin-binding site mediates complex retention and degradation but not cell surface binding or internalization. J Biol Chem 2000; 275 (26): 19628-19637.
39. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, Bdeir K, Dumler I, Marks MS, Parfyonova Y, Tkachuk VA, Higazi AA, Cines DB,. Nuclear translocation of urokinase-type plasminogen activator. Blood 2008; 112 (1): 100-110.
40. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP,. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274 (19): 13066-13076.
41. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM,. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405 (2): 157-162.
42. Prudova A, auf dem Keller U, Butler GS, Overall CM,. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 2010; 9 (5): 894-911.
43. Huber R, Carrell RW,. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28 (23): 8951-8966.
44. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G,. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37 (6): 375-536.
45. Dematteis A, Miranda SD, Novella ML, Maldonado C, Ponce RH, Maldera JA, Cuasnicu PS, Coronel CE,. Rat caltrin protein modulates the acrosomal exocytosis during sperm capacitation. Biol Reprod 2008; 79 (3): 493-500.
46. Murer V, Spetz JF, Hengst U, Altrogge LM, de Agostini A, Monard D,. Male fertility defects in mice lacking the serine protease inhibitor protease nexin-1. Proc Natl Acad Sci USA 2001; 98 (6): 3029-3033.
47. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC,. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368 (6470): 419-424.
48. McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, Ramnarine VR, Jurisica I, Mallof C, Lam W, Bristow RG, Muschel RJ,. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest 2012; 122 (11): 4025-4036.
49. Gonzalez-Gronow M, Grenett HE, Gawdi G, Pizzo SV,. Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res 2005; 303 (1): 22-31.
50. Andreasen PA, Kjoller L, Christensen L, Duffy MJ,. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72 (1): 1-22.